Xalkori (crizotinib)

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

ALK inhibitor

Related drugs:

ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK translocation	Soft Tissue Sarcoma	ALK translocation	Soft Tissue Sarcoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 fusion	Melanoma	ROS1 fusion	Melanoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK fusion	Melanoma	ALK fusion	Melanoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B
ALK positive	Lymphoma	ALK positive	Lymphoma	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B
ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ALK positive	Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	crizotinib Sensitive: C1 - Off-label crizotinib Sensitive : C1	crizotinib Sensitive: C1 - Off-label crizotinib Sensitive : C1
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria bevacizumab + crizotinib Sensitive : C2	bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria bevacizumab + crizotinib Sensitive : C2
MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET amplification	Renal Cell Carcinoma	MET amplification	Renal Cell Carcinoma	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET amplification	Head and Neck Cancer	MET amplification	Head and Neck Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET amplification + MET Exon 14 mutation	Non Small Cell Lung Cancer	MET amplification + MET Exon 14 mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ROS1 rearrangement	Lung Cancer	ROS1 rearrangement	Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK translocation	Non Small Cell Lung Cancer	ALK translocation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET exon 14 mutation	Solid Tumor	MET exon 14 mutation	Solid Tumor	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK rearrangement	Lung Cancer	ALK rearrangement	Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK rearrangement	Lung Cancer	ALK rearrangement	Lung Cancer	crizotinib + lorlatinib Sensitive: C2 – Inclusion Criteria crizotinib + lorlatinib Sensitive : C2	crizotinib + lorlatinib Sensitive: C2 – Inclusion Criteria crizotinib + lorlatinib Sensitive : C2
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	bevacizumab + crizotinib Sensitive: C3 – Early Trials bevacizumab + crizotinib Sensitive : C3	bevacizumab + crizotinib Sensitive: C3 – Early Trials bevacizumab + crizotinib Sensitive : C3

Xalkori (crizotinib)

Associations
(312)

Associations
(312)

Xalkori (crizotinib)

Associations(312)

Associations(312)

Associations
(312)

Associations
(312)